Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy

This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.

NCT Number	NCT07199413
Lead Sponsor	Medical College of Wisconsin
Conditions	Brain Metastases, Leptomeningeal Metastasis
Start Date	2026-06-15
Primary Completion	2029-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-17